Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02041260
Title A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Exelixis
Indications

thyroid gland cancer

Therapies

Cabozantinib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field